-transparent.png){kind=logo}
Forty-six advanced ovarian cancer patients treated with conventional modalities with the addition of bacillus Calmette-Guérin (BCG) immunotherapy showed prolonged survival when compared to controls not given BCG. Although the data suggest enhancement of survival with the addition of BCG to conventional treatment, the fact remains that disease recurrence ultimately claims the lives of most of these patients. Nonetheless, patients are surviving longer in the face of advanced disease.
Related Publications
R A Pattillo, and
R Komaki, and
M Reynolds, and
J Robles
May 2021,
Vaccines,
R A Pattillo, and
R Komaki, and
M Reynolds, and
J Robles
August 2013,
BJU international,
R A Pattillo, and
R Komaki, and
M Reynolds, and
J Robles
November 2001,
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie,
R A Pattillo, and
R Komaki, and
M Reynolds, and
J Robles
December 1979,
Urology,
R A Pattillo, and
R Komaki, and
M Reynolds, and
J Robles
August 1992,
The Urologic clinics of North America,
R A Pattillo, and
R Komaki, and
M Reynolds, and
J Robles
August 1992,
The Urologic clinics of North America,
R A Pattillo, and
R Komaki, and
M Reynolds, and
J Robles
May 2008,
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie,
R A Pattillo, and
R Komaki, and
M Reynolds, and
J Robles
May 2008,
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie,
R A Pattillo, and
R Komaki, and
M Reynolds, and
J Robles
February 2016,
Cancer immunology, immunotherapy : CII,
R A Pattillo, and
R Komaki, and
M Reynolds, and
J Robles
January 2015,
Expert review of anticancer therapy,
